Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

August 31, 2026

Conditions

Esophageal Cancer

Interventions

DRUG

Carboplatin

neoadjuvant chemotherapy，2cycles.

DRUG

Nab paclitaxel

neoadjuvant chemotherapy，2cycles.

DRUG

Sintilimab

neoadjuvant immunotherapy，2cycles.

Trial Locations (1)

RECRUITING

West-China Hospital, Chengdu

All Listed Sponsors

lead

Sichuan University

OTHER